1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
REACHing Communities (REACH) Consortium (U01) Clinical Trials Optional is sponsored by Food and Drug Administration. REACHing Communities (REACH) Consortium (U01) Clinical Trials Optional is a forecasted funding opportunity on Grants. gov from Food and Drug Administration.
Fiscal Year: 2025. Assistance Listing Number(s): 93. 103.
<p>This purpose of this notice of funding opportunity (NOFO) is for FDA Office of Minority Health and Health Equity's (OMHHE) Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH).
The consortium will consist of multiple cooperative agreement (U01) recipients that will strengthen and advance minority health and health equity focused research, outreach, and communications as well as support training and mentoring of diverse students, fellow...
Get alerted about grants like this
Save a search for “Food and Drug Administration” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicant types: [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object]. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Orphan Products Grants Program is sponsored by U.S. Food and Drug Administration (FDA). This program awards grants to clinical investigators to support the development of safe and effective medical products (drugs, biologics, medical devices, and foods for medical purposes) for patients with rare diseases or conditions, defined as those affecting fewer than 200,000 persons in the United States. Urea cycle disorders fall under this definition. The program funds clinical trials and natural history studies.
Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) is sponsored by National Science Foundation (NSF) / National Institutes of Health (NIH) / Food and Drug Administration (FDA). This program supports interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications, with a particular focus on digital, in silico models…
The NSF FDT-BioTech program, a joint initiative of the National Science Foundation, National Institutes of Health, and the Food and Drug Administration, supports inherently interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications. The program has a particular focus on digital, in silico models used in the evaluation of medical devices. Projects combine AI and machine learning with mathematical sciences and domain knowledge to develop computational models that can simulate biological systems, predict treatment outcomes, and accelerate medical device evaluation. Each project requires at least two collaborating Senior/Key Personnel with participation from both mathematical sciences and at least one domain knowledge discipline. The program runs annually with a deadline on the first Monday in May.